The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
Official Title: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Study ID: NCT02223208
Brief Summary: This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.
Detailed Description: PHASE I A1) Induction phase Ro-CHOEP-21 x 3 cycles * Romidepsin (dose escalation) starting dose: 12mg/ms iv day +1 and +8. Dose modification according to toxicity (14mg/ms day +1 and +8; 10mg/ms day +1 and +8; 8mg/ms day +1 and +8); * CHOEP-21 (Doxorubicin 50 mg/ms iv day +1; Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1; Cyclophosphamide 750 mg/ms iv day +1; Etoposide 100mg/ms iv from day +1 to +3; Prednisone100 mg orally from days +1 to +5). According to the response achieved after the first 3 Ro-CHOEP-21 cycles: * PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2 * SD or PD: Treatment failures, proceed to salvage according to each institutional policy. A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting. According to response achieved after 6 Ro-CHOEP-21 cycles: CR: BEAM or FEAM or CEAM followed by auto-SCT PR * Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility. * when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT. * Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy. PHASE II A1) Induction phase Ro-CHOEP-21 x 3 cycles * Romidepsin dose according to phase I iv day +1 and +8 * Doxorubicin 50 mg/ms iv day +1, * Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1, * Cyclophosphamide 750 mg/ms iv day +1, * Etoposide 100mg/ms iv from day +1 to +3 * Prednisone100 mg orally from days +1 to +5 According to the response achieved after the first 3 Ro-CHOEP-21 cycles: * PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2 * SD or PD: Treatment failures, proceed to salvage according to each institutional policy. A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting. According to response achieved after 6 Ro-CHOEP-21 cycles: CR: BEAM or FEAM or CEAM followed by auto-SCT PR * Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility. * when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT. * Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
Policlinico S. Orsola Malpighi, Bologna, BO, Italy
Spedali Civili, Brescia, BS, Italy
Ospedale Businco, Cagliari, CA, Italy
Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola, Meldola, FC, Italy
IRCCS AOU San Martino - Clinica Ematologica, Genova, GE, Italy
IRCCS AOU San Martino - UO Ematologia 1, Genova, GE, Italy
Istituto Clinico Humanitas, Rozzano, Milano, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, MI, Italy
Fondazione IRCCS "Istituto Nazionale dei Tumori", Milano, MI, Italy
Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, MI, Italy
AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello), Palermo, PA, Italy
IRCCS Centro di Riferimento Oncologico (CRO), Aviano, PN, Italy
AOU di Parma, Parma, PR, Italy
Fondazione IRCCS - Policlinico San Matteo, Pavia, PV, Italy
IRCCS Arcispedale "Santa Maria Nuova", Reggio Emilia, RE, Italy
Ospedale degli Infermi, Rimini, RN, Italy
AO Città della Salute e della Scienza - Ematologia 1U, Torino, TO, Italy
AO Città della Salute e della Scienza - SC Ematologia, Torino, TO, Italy
AOU "Santa Maria della Misericordia", Udine, UD, Italy
Ospedale Borgo Roma, Verona, VR, Italy
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, , Italy
Ospedale Maggiore della Carità - SCDU Ematologia, Novara, , Italy
A.O. di Perugia - Santa Maria della Misericordia, Perugia, , Italy
Ospedale G. Da Saliceto - AUSL di Piacenza, Piacenza, , Italy
UO Ematologia Ospedale S.Maria delle Croci, Ravenna, , Italy
Name: Paolo Corradini, Prof
Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Role: PRINCIPAL_INVESTIGATOR